Cost-Effectiveness of Three Poliovirus Immunization Schedules in Shanghai, China
1
Shanghai Municipal Center for Disease Control and Prevention, Institute of Immunization, Shanghai 200336, China
2
Ministry of Education Key Laboratory of Public Health Safety, Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
*
Author to whom correspondence should be addressed.
Academic Editors: Ifran A. Rather, Suriya Rehman, Yan Yan Hor and Lew Lee Ching
Vaccines 2021, 9(10), 1062; https://doi.org/10.3390/vaccines9101062
Received: 24 August 2021
/
Revised: 18 September 2021
/
Accepted: 19 September 2021
/
Published: 23 September 2021
(This article belongs to the Special Issue Viral Diseases and the Existing Comorbidities: An Overview of Disease Development, Progression, and Therapeutics)
In Shanghai, China, a polio immunization schedule of four inactivated polio vaccines (IPV) has been implemented since 2020, replacing the schedules of a combination of two IPVs and two bivalent live attenuated oral polio vaccines (bOPV), and four trivalent live attenuated oral polio vaccines (tOPV). This study aimed to assess the cost-effectiveness of these three schedules in infants born in 2016, in preventing vaccine-associated paralytic poliomyelitis (VAPP). We performed a decision tree model and estimated incremental cost-effectiveness ratio (ICER). Compared to the four-tOPV schedule, the two-IPV-two-bOPV schedule averted 1.2 VAPP cases and 16.83 disability-adjusted life years (DALY) annually; while the four-IPV schedule averted 1.35 VAPP cases and 18.96 DALY annually. Consequently, ICERVAPP and ICERDALY were substantially high for two-IPV-two-bOPV (CNY 12.96 million and 0.93 million), and four-IPV (CNY 21.24 million and 1.52 million). Moreover, net monetary benefit of the two-IPV-two-bOPV and four-IPV schedules was highest when the cost of IPV was hypothesized to be less than CNY 23.75 or CNY 9.11, respectively, and willingness-to-pay was hypothesized as CNY 0.6 million in averting one VAPP-induced DALY. IPV-containing schedules are currently cost-ineffective in Shanghai. They may be cost-effective by reducing the prices of IPV, which may accelerate polio eradication in Chinese settings.
View Full-Text
Keywords:
poliomyelitis; poliovirus; live attenuated oral polio vaccine; inactivated polio vaccine; cost-effectiveness analysis; cost-benefit analysis
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Ren, J.; Maimaiti, H.; Sun, X.; Huang, Z.; Liu, J.; Yang, J.; Li, Z.; Bai, Q.; Lu, Y. Cost-Effectiveness of Three Poliovirus Immunization Schedules in Shanghai, China. Vaccines 2021, 9, 1062. https://doi.org/10.3390/vaccines9101062
AMA Style
Ren J, Maimaiti H, Sun X, Huang Z, Liu J, Yang J, Li Z, Bai Q, Lu Y. Cost-Effectiveness of Three Poliovirus Immunization Schedules in Shanghai, China. Vaccines. 2021; 9(10):1062. https://doi.org/10.3390/vaccines9101062
Chicago/Turabian StyleRen, Jia, Hairenguli Maimaiti, Xiaodong Sun, Zhuoying Huang, Jiechen Liu, Jianping Yang, Zhi Li, Qingrui Bai, and Yihan Lu. 2021. "Cost-Effectiveness of Three Poliovirus Immunization Schedules in Shanghai, China" Vaccines 9, no. 10: 1062. https://doi.org/10.3390/vaccines9101062
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
